Analysts Issue Forecasts for Cardiovascular Systems, Inc.’s Q1 2024 Earnings (NASDAQ:CSII)

Cardiovascular Systems, Inc. (NASDAQ:CSII – Get Rating) – Oppenheimer issued their Q1 2024 EPS estimates for Cardiovascular Systems in a report issued on Thursday, August 4th. Oppenheimer analyst S. Kalia expects that the medical device company will post earnings per share of ($0.14) for the quarter. The consensus estimate for Cardiovascular Systems’ current full-year earnings is ($0.69) per share. Oppenheimer also issued estimates for Cardiovascular Systems’ Q2 2024 earnings at ($0.13) EPS, Q4 2024 earnings at ($0.07) EPS and FY2024 earnings at ($0.44) EPS.

Cardiovascular Systems (NASDAQ:CSII – Get Rating) last released its quarterly earnings results on Wednesday, May 4th. The medical device company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.03. Cardiovascular Systems had a negative net margin of 15.64% and a negative return on equity of 14.40%. The business had revenue of $56.22 million for the quarter, compared to analyst estimates of $57.38 million. During the same period last year, the firm earned ($0.15) earnings per share. Cardiovascular Systems’s revenue for the quarter was down 11.1% compared to the same quarter last year.

Cardiovascular Systems Price Performance

NASDAQ:CSII opened at $16.55 on Friday. Cardiovascular Systems has a 52 week low of $13.41 and a 52 week high of $39.37. The firm has a market cap of $674.99 million, a price-to-earnings ratio of -17.42 and a beta of 0.94. The firm’s 50-day simple moving average is $15.16 and its 200 day simple moving average is $17.82. The company has a debt-to-equity ratio of 0.08, a quick ratio of 4.58 and a current ratio of 6.05.

Insider Buying and Selling

In other Cardiovascular Systems news, CFO Jeffrey S. Points purchased 3,000 shares of the stock in a transaction that occurred on Friday, May 20th. The shares were acquired at an average cost of $14.50 per share, with a total value of $43,500.00. Following the completion of the transaction, the chief financial officer now owns 109,312 shares in the company, valued at $1,585,024. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Cardiovascular Systems

Large investors have recently bought and sold shares of the company. Signaturefd LLC grew its stake in Cardiovascular Systems by 8,110.3% during the first quarter. Signaturefd LLC now owns 2,381 shares of the medical device company’s stock worth $54,000 after buying an additional 2,352 shares in the last quarter. Acadian Asset Management LLC grew its stake in Cardiovascular Systems by 294.7% during the fourth quarter. Acadian Asset Management LLC now owns 2,684 shares of the medical device company’s stock worth $50,000 after buying an additional 2,004 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in Cardiovascular Systems by 32.1% during the first quarter. PNC Financial Services Group Inc. now owns 3,025 shares of the medical device company’s stock worth $68,000 after buying an additional 735 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in Cardiovascular Systems by 54.3% during the first quarter. Nisa Investment Advisors LLC now owns 3,495 shares of the medical device company’s stock worth $79,000 after buying an additional 1,230 shares in the last quarter. Finally, Point72 Hong Kong Ltd acquired a new stake in Cardiovascular Systems during the fourth quarter worth about $74,000. 91.24% of the stock is currently owned by institutional investors and hedge funds.

Cardiovascular Systems Company Profile

(Get Rating)

Cardiovascular Systems, Inc, a medical device company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products, which are catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products.